Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler » 06:59
09/14/21
09/14
06:59
09/14/21
06:59
ABMD

Abiomed

$351.52 /

-9.83 (-2.72%)

, APEN

Apollo Endosurgery

$9.76 /

-0.235 (-2.35%)

, BSX

Boston Scientific

$44.23 /

-0.23 (-0.52%)

, CVRX

CVRx

$18.32 /

-0.66 (-3.48%)

, LIVN

LivaNova

$83.46 /

+0.63 (+0.76%)

, LUNG

Pulmonx

$38.30 /

-0.51 (-1.31%)

, MASI

Masimo

$269.47 /

-4.96 (-1.81%)

, MDT

Medtronic

$130.04 /

-1.13 (-0.86%)

, MMSI

Merit Medical

$71.63 /

-0.37 (-0.51%)

, NVCR

Novocure

$129.54 /

-2.29 (-1.74%)

, PODD

Insulet

$295.08 /

-0.765 (-0.26%)

, STIM

Neuronetics

$6.79 /

-0.06 (-0.88%)

, SWAV

ShockWave Medical

$212.23 /

-5.49 (-2.52%)

, VAPO

Vapotherm

$28.51 /

-0.16 (-0.56%)

, EW

Edwards Lifesciences

$119.36 /

-1.55 (-1.28%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien says the Centers for Medicare and Medicaid Services issued a notice proposing to fully repeal Medicare Coverage of Innovative Technology. There's a comment period and the program could go into effect, but that scenario is unlikely, O'Brien tells investors in a research note. The analyst is uncertain of the next steps, but he anticipates the industry will attempt to resurrect the program in a different form eventually. He views the update as a net negative for the medical technology sector. From a stock perspective, the large caps in coverage are likely the beneficiaries of the update, whereas the smaller providers are more adversely impacted, says O'Brien.

ShowHide Related Items >><<
VAPO Vapotherm
$28.51 /

-0.16 (-0.56%)

SWAV ShockWave Medical
$212.23 /

-5.49 (-2.52%)

STIM Neuronetics
$6.79 /

-0.06 (-0.88%)

PODD Insulet
$295.08 /

-0.765 (-0.26%)

NVCR Novocure
$129.54 /

-2.29 (-1.74%)

MMSI Merit Medical
$71.63 /

-0.37 (-0.51%)

MDT Medtronic
$130.04 /

-1.13 (-0.86%)

MASI Masimo
$269.47 /

-4.96 (-1.81%)

LUNG Pulmonx
$38.30 /

-0.51 (-1.31%)

LIVN LivaNova
$83.46 /

+0.63 (+0.76%)

EW Edwards Lifesciences
$119.36 /

-1.55 (-1.28%)

CVRX CVRx
$18.32 /

-0.66 (-3.48%)

BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

APEN Apollo Endosurgery
$9.76 /

-0.235 (-2.35%)

ABMD Abiomed
$351.52 /

-9.83 (-2.72%)

ABMD Abiomed
$351.52 /

-9.83 (-2.72%)

08/06/21 Deutsche Bank
Abiomed price target raised to $410 from $360 at Deutsche Bank
06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
APEN Apollo Endosurgery
$9.76 /

-0.235 (-2.35%)

09/09/21 Stephens
Apollo Endosurgery initiated with an Overweight at Stephens
08/04/21 Lake Street
Apollo Endosurgery price target raised to $14 from $12 at Lake Street
08/04/21 Piper Sandler
Apollo Endosurgery price target raised to $14 from $11 at Piper Sandler
07/19/21 Lake Street
Lake Street 'strongly' supports Apollo Endosurgery appointing Black as CFO
BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
08/31/21 Barclays
Abbott's Amulet could become 'needle mover,' says Barclays
08/30/21 Piper Sandler
Boston Scientific's Watchman still well positioned, says Piper Sandler
07/27/21 Piper Sandler
Boston Scientific well positioned after 'strong' Q2, says Piper Sandler
CVRX CVRx
$18.32 /

-0.66 (-3.48%)

07/26/21 JPMorgan
CVRx initiated with an Overweight at JPMorgan
07/26/21 Canaccord
CVRx initiated with a Buy at Canaccord
07/26/21 William Blair
CVRx initiated with an Outperform at William Blair
07/26/21 Piper Sandler
CVRx initiated with an Overweight at Piper Sandler
LIVN LivaNova
$83.46 /

+0.63 (+0.76%)

08/20/21 Needham
Needham adds LivaNova to Conviction Buy, price target raised to $117
08/17/21 Baird
LivaNova price target raised to $105 from $100 at Baird
08/16/21 Piper Sandler
Piper bullish on LivaNova after early retirement of term loan, updated guidance
07/28/21 Piper Sandler
Piper ups LivaNova target to $100, says guidance could prove conservative
LUNG Pulmonx
$38.30 /

-0.51 (-1.31%)

08/04/21 Canaccord
Pulmonx price target lowered to $53 from $65 at Canaccord
07/22/21 Piper Sandler
Pulmonx setup into Q2 'looks a bit more intriguing,' says Piper Sandler
04/01/21 Citi
Pulmonx initiated with a Buy at Citi
03/25/21 Piper Sandler
Pulmonx initiated with a Neutral at Piper Sandler
MASI Masimo
$269.47 /

-4.96 (-1.81%)

07/28/21 Piper Sandler
Masimo price target raised to $300 from $295 at Piper Sandler
07/01/21 Piper Sandler
Masimo ITC request may signal push into consumer products, says Piper Sandler
05/20/21 Piper Sandler
Masimo job postings show progress on opioid launch, says Piper Sandler
04/27/21 Piper Sandler
Masimo remains core holding for medtech investors, says Piper Sandler
MDT Medtronic
$130.04 /

-1.13 (-0.86%)

08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
08/25/21 Wells Fargo
Medtronic price target raised to $151 from $140 at Wells Fargo
MMSI Merit Medical
$71.63 /

-0.37 (-0.51%)

07/30/21 Barrington
Merit Medical price target raised to $79 from $71 at Barrington
07/30/21 Needham
Merit Medical price target raised to $83 from $73 at Needham
07/30/21 Piper Sandler
Merit Medical price target raised to $79 from $73 at Piper Sandler
05/17/21 Barrington
Merit Medical will be $100 stock within 3-5 years, says Barrington
NVCR Novocure
$129.54 /

-2.29 (-1.74%)

07/30/21 Mizuho
Novocure price target lowered to $200 from $229 at Mizuho
07/29/21 Piper Sandler
Novocure price target lowered to $235 from $240 at Piper Sandler
07/09/21 Piper Sandler
Novocure price target raised to $240 from $235 at Piper Sandler
07/02/21 Oppenheimer
Novocure selloff on study results 'appropriate,' says Oppenheimer
PODD Insulet
$295.08 /

-0.765 (-0.26%)

08/06/21 Canaccord
Insulet price target raised to $300 from $280
08/06/21 Citi
Insulet price target raised to $325 from $310 at Citi
08/05/21 Piper Sandler
Insulet price target raised to $262 from $250 at Piper Sandler
07/21/21 Cowen
Insulet price target raised to $310 from $285 at Cowen
STIM Neuronetics
$6.79 /

-0.06 (-0.88%)

08/03/21 Piper Sandler
Neuronetics price target lowered to $12 from $21 at Piper Sandler
05/04/21 Piper Sandler
Neuronetics' sessions business starting to bear fruit, says Piper Sandler
03/02/21 Piper Sandler
Neuronetics price target lowered to $25 from $27 at Piper Sandler
01/27/21 JMP Securities
Neuronetics price target raised to $23 from $15 at JMP Securities
SWAV ShockWave Medical
$212.23 /

-5.49 (-2.52%)

08/03/21 Piper Sandler
CMS new-tech-add-on payment approved for ShockWave, says Piper Sandler
08/03/21 Piper Sandler
AMA meeting agenda positive for ShockWave Medical, says Piper Sandler
07/15/21 Piper Sandler
Piper Sandler sees minimal exposure risk to Shockwave Medical from CMS rate cuts
07/15/21 SVB Leerink
ShockWave Medical initiated with an Outperform at SVB Leerink
VAPO Vapotherm
$28.51 /

-0.16 (-0.56%)

09/08/21 Piper Sandler
Delta variant driving sizable upside to Vapotherm's Q3, says Piper Sandler
02/25/21 Piper Sandler
Vapotherm price target lowered to $36 from $39 at Piper Sandler
01/15/21 Piper Sandler
Vapotherm price target raised to $39 from $36 at Piper Sandler
01/13/21 Piper Sandler
Vapotherm remains top small pick at Piper Sandler
EW Edwards Lifesciences
$119.36 /

-1.55 (-1.28%)

07/30/21 Canaccord
Edwards Lifesciences price target raised to $124 from $103 at Canaccord
07/30/21 Jefferies
Edwards Lifesciences price target raised to $130 from $110 at Jefferies
07/30/21 Wells Fargo
Edwards Lifesciences price target raised to $115 from $93 at Wells Fargo
07/30/21 Deutsche Bank
Edwards Lifesciences price target raised to $113 from $84 at Deutsche Bank
VAPO Vapotherm
$28.51 /

-0.16 (-0.56%)

SWAV ShockWave Medical
$212.23 /

-5.49 (-2.52%)

STIM Neuronetics
$6.79 /

-0.06 (-0.88%)

PODD Insulet
$295.08 /

-0.765 (-0.26%)

NVCR Novocure
$129.54 /

-2.29 (-1.74%)

MMSI Merit Medical
$71.63 /

-0.37 (-0.51%)

MDT Medtronic
$130.04 /

-1.13 (-0.86%)

MASI Masimo
$269.47 /

-4.96 (-1.81%)

LUNG Pulmonx
$38.30 /

-0.51 (-1.31%)

LIVN LivaNova
$83.46 /

+0.63 (+0.76%)

EW Edwards Lifesciences
$119.36 /

-1.55 (-1.28%)

BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

ABMD Abiomed
$351.52 /

-9.83 (-2.72%)

  • 04
    Aug
  • 13
    Jul
  • 30
    Jun
  • 29
    Jan
  • 01
    Oct
BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

ABMD Abiomed
$351.52 /

-9.83 (-2.72%)

STIM Neuronetics
$6.79 /

-0.06 (-0.88%)

PODD Insulet
$295.08 /

-0.765 (-0.26%)

NVCR Novocure
$129.54 /

-2.29 (-1.74%)

MMSI Merit Medical
$71.63 /

-0.37 (-0.51%)

MDT Medtronic
$130.04 /

-1.13 (-0.86%)

MASI Masimo
$269.47 /

-4.96 (-1.81%)

LIVN LivaNova
$83.46 /

+0.63 (+0.76%)

EW Edwards Lifesciences
$119.36 /

-1.55 (-1.28%)

CVRX CVRx
$18.32 /

-0.66 (-3.48%)

BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

MDT Medtronic
$130.04 /

-1.13 (-0.86%)

EW Edwards Lifesciences
$119.36 /

-1.55 (-1.28%)

BSX Boston Scientific
$44.23 /

-0.23 (-0.52%)

ABMD Abiomed
$351.52 /

-9.83 (-2.72%)

Over a month ago
Hot Stocks
FDA grants breakthrough device designation to Impella ECP » 08:11
08/18/21
08/18
08:11
08/18/21
08:11
ABMD

Abiomed

$328.98 /

+4.69 (+1.45%)

The United States Food…

The United States Food and Drug Administration, FDA, has granted breakthrough device designation to Abiomed's mpella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols and pre-market approval application. Impella ECP, the world's smallest heart pump, is placed percutaneously into the heart's left ventricle, expands, and supports the heart's pumping function, providing flow greater than 3.5 L/min. Impella ECP is the smallest heart pump in the world and the first to be compatible with small bore access and closure techniques. It measures 9 French in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart's pumping function, providing flow greater than 3.5 L/min. "This is yet another validation from the FDA of the clinical benefits of Impella technology and an affirmation of the innovative nature of Impella ECP which, due to its smaller vascular access size, has the potential to provide even safer procedures and be available to more patients who need hemodynamic support for coronary revascularization," said Chuck Simonton, MD, Abiomed's chief medical officer.

ShowHide Related Items >><<
ABMD Abiomed
$328.98 /

+4.69 (+1.45%)

ABMD Abiomed
$328.98 /

+4.69 (+1.45%)

08/06/21 Deutsche Bank
Abiomed price target raised to $410 from $360 at Deutsche Bank
06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
ABMD Abiomed
$328.98 /

+4.69 (+1.45%)

ABMD Abiomed
$328.98 /

+4.69 (+1.45%)

ABMD Abiomed
$328.98 /

+4.69 (+1.45%)

Hot Stocks
Abiomed dips as traders circulate FDA 'Medsun' report » 09:51
08/09/21
08/09
09:51
08/09/21
09:51
ABMD

Abiomed

$346.00 /

-0.03 (-0.01%)

Shares of Abiomed are…

Shares of Abiomed are down about 1% to $343.49 in early trading as traders circulate a FDA "Medsun" report dated August 5. The report states in part: "In examining the pump catheter, there was notable thrombic material around the discharge ports of the pump, but it is unknown if this was present at the time of explant or formed later while sitting in a bag for over a day. The catheter will be given to the manufacturer for their evaluation. All pieces were removed, and an x-ray was taken. Results were negative." Reference Link

ShowHide Related Items >><<
ABMD Abiomed
$346.00 /

-0.03 (-0.01%)

ABMD Abiomed
$346.00 /

-0.03 (-0.01%)

08/06/21 Deutsche Bank
Abiomed price target raised to $410 from $360 at Deutsche Bank
06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
ABMD Abiomed
$346.00 /

-0.03 (-0.01%)

ABMD Abiomed
$346.00 /

-0.03 (-0.01%)

ABMD Abiomed
$346.00 /

-0.03 (-0.01%)

Recommendations
Abiomed price target raised to $410 from $360 at Deutsche Bank » 07:02
08/06/21
08/06
07:02
08/06/21
07:02
ABMD

Abiomed

$349.27 /

+17.74 (+5.35%)

Deutsche Bank analyst…

Deutsche Bank analyst Pito Chickering raised the firm's price target on Abiomed to $410 from $360 and keeps a Buy rating on the shares. The company reported an "all-around high-quality" fiscal Q1, Chickering tells investors in a research note.

ShowHide Related Items >><<
ABMD Abiomed
$349.27 /

+17.74 (+5.35%)

ABMD Abiomed
$349.27 /

+17.74 (+5.35%)

06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
ABMD Abiomed
$349.27 /

+17.74 (+5.35%)

ABMD Abiomed
$349.27 /

+17.74 (+5.35%)

ABMD Abiomed
$349.27 /

+17.74 (+5.35%)

Earnings
Abiomed raises FY22 revenue view to $1.03B-$1.05B, consensus $1.02B » 16:19
08/04/21
08/04
16:19
08/04/21
16:19
ABMD

Abiomed

$331.17 /

+4.82 (+1.48%)

Previous view…

Previous view $990M-$1.03B. The company is increasing fiscal year 2022 global revenue and now expects it to be in the range of $1,030 million to $1,050 million, representing 22% to 24% growth compared to fiscal year 2021, an increase from our original guidance of $990 million to $1,030 million, or 17% to 22% growth compared to fiscal year 2021. The company expects its fiscal year 2022 non-GAAP operating margin* to be in the range of 24% to 26%.

ShowHide Related Items >><<
ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

Earnings
Abiomed reports Q1 adjusted EPS $1.10, consensus $1.05 » 16:18
08/04/21
08/04
16:18
08/04/21
16:18
ABMD

Abiomed

$331.17 /

+4.82 (+1.48%)

Reports Q1 revenue…

Reports Q1 revenue $252.6M, consensus $240.91M. "Q1 was a solid start with record global revenue and patient utilization in US, Europe and Japan, and we believe we are well-positioned for success in FY22," said Michael R. Minogue, Abiomed's Chairman, President and Chief Executive Officer. "We will continue to create and deliver value by successfully advancing our innovation, clinical research and commercial distribution. We remain steadfast to creating the field of heart recovery and driving a new standard of care for circulatory support."

ShowHide Related Items >><<
ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

ABMD Abiomed
$331.17 /

+4.82 (+1.48%)

Hot Stocks
Abiomed announces Impella RP with SmartAssist receives FDA pre-market approval » 08:04
06/29/21
06/29
08:04
06/29/21
08:04
ABMD

Abiomed

$312.23 /

+0.96 (+0.31%)

Abiomed's newest…

Abiomed's newest right heart pump, the Impella RP with SmartAssist, has received FDA pre-market approval, or PMA, as safe and effective to treat acute right heart failure for up to 14 days.

ShowHide Related Items >><<
ABMD Abiomed
$312.23 /

+0.96 (+0.31%)

ABMD Abiomed
$312.23 /

+0.96 (+0.31%)

06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
ABMD Abiomed
$312.23 /

+0.96 (+0.31%)

ABMD Abiomed
$312.23 /

+0.96 (+0.31%)

ABMD Abiomed
$312.23 /

+0.96 (+0.31%)

Over a quarter ago
Options
Early notable gainers among liquid option names on June 18th » 09:55
06/18/21
06/18
09:55
06/18/21
09:55
NVDA

Nvidia

$761.60 /

+15.08 (+2.02%)

, ADBE

Adobe

$560.64 /

+9.69 (+1.76%)

, LEN

Lennar

$96.46 /

+1.89 (+2.00%)

, ABMD

Abiomed

$316.00 /

+3.21 (+1.03%)

, OXY

Occidental Petroleum

$28.36 /

+0.14 (+0.50%)

Notable gainers among…

Notable gainers among liquid option names this morning include NVIDIA (NVDA) $763.47 +16.88, Adobe (ADBE) $561.26 +10.26, Lennar (LEN) $96.22 +1.56, Abiomed (ABMD) $316.43 +3.80, and Occidental Petroleum (OXY) $28.54 +0.32.

ShowHide Related Items >><<
OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

LEN Lennar
$96.46 /

+1.89 (+2.00%)

ADBE Adobe
$560.64 /

+9.69 (+1.76%)

ABMD Abiomed
$316.00 /

+3.21 (+1.03%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

06/18/21 Jefferies
Intel price target lowered to $54 from $59 at Jefferies
06/18/21 BofA
BofA ups Nvidia target to $900, sees data center sales tripling by 2025
06/17/21 Jefferies
Nvidia price target raised to $854 from $740 at Jefferies
06/08/21 Rosenblatt
Marvell price target raised to $70 from $60 at Rosenblatt
ADBE Adobe
$560.64 /

+9.69 (+1.76%)

06/18/21 JPMorgan
Adobe price target raised to $660 from $595 at JPMorgan
06/18/21 Evercore ISI
Adobe price target raised to $625 from $550 at Evercore ISI
06/18/21 BMO Capital
Adobe price target raised to $630 from $585 at BMO Capital
06/18/21 Goldman Sachs
Adobe price target raised to $665 from $580 at Goldman Sachs
LEN Lennar
$96.46 /

+1.89 (+2.00%)

06/18/21 Evercore ISI
Lennar price target raised to $160 from $121 at Evercore ISI
06/18/21 JPMorgan
JPMorgan upgrades Lennar with transformation not reflected in shares
06/18/21 JMP Securities
Lennar price target raised to $130 from $120 at JMP Securities
06/18/21 BTIG
Lennar price target raised to $127 from $117 at BTIG
ABMD Abiomed
$316.00 /

+3.21 (+1.03%)

06/18/21 Deutsche Bank
Abiomed initiated with a Buy at Deutsche Bank
06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

06/18/21 Morgan Stanley
Occidental upgraded to Overweight from Equal Weight at Morgan Stanley
06/03/21 Barclays
Occidental Petroleum upgraded to Overweight from Equal Weight at Barclays
05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 Goldman Sachs
Occidental Petroleum upgraded to Buy from Neutral at Goldman Sachs
OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

LEN Lennar
$96.46 /

+1.89 (+2.00%)

ADBE Adobe
$560.64 /

+9.69 (+1.76%)

ABMD Abiomed
$316.00 /

+3.21 (+1.03%)

OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

LEN Lennar
$96.46 /

+1.89 (+2.00%)

ABMD Abiomed
$316.00 /

+3.21 (+1.03%)

OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

LEN Lennar
$96.46 /

+1.89 (+2.00%)

ADBE Adobe
$560.64 /

+9.69 (+1.76%)

OXY Occidental Petroleum
$28.36 /

+0.14 (+0.50%)

NVDA Nvidia
$761.60 /

+15.08 (+2.02%)

LEN Lennar
$96.46 /

+1.89 (+2.00%)

ADBE Adobe
$560.64 /

+9.69 (+1.76%)

Initiation
Abiomed initiated with a Buy at Deutsche Bank » 06:47
06/18/21
06/18
06:47
06/18/21
06:47
ABMD

Abiomed

$312.81 /

+10.1 (+3.34%)

Deutsche Bank analyst…

Deutsche Bank analyst Pito Chickering initiated coverage of Abiomed with a Buy rating and $360 price target. Despite concerns on Wall Street over how useful the Impella pump is versus a standard balloon pump, Abiomed revenue has grown from $100M in 2011 to $847M in 2021, Chickering tells investors in a research note. The analyst believes this shows the underlying demand from physicians and clinical merits of the technology.

ShowHide Related Items >><<
ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

06/18/21 Piper Sandler
Abiomed confident in near-term business recovery, says Piper Sandler
06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
04/29/21 Piper Sandler
Abiomed earnings selloff a buying opportunity, says Piper Sandler
ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

Recommendations
Abiomed confident in near-term business recovery, says Piper Sandler » 05:02
06/18/21
06/18
05:02
06/18/21
05:02
ABMD

Abiomed

$312.81 /

+10.1 (+3.34%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien recommends purchase of Abiomed shares after hosting meetings with management. The company seems confident in the recovery of the business in the near term, O'Brien tells investors in a research note. Investments in the distribution channel and clinical trials are ramping up, which will weigh on operating margins, but Abiomed is taking steps needed to solidify areas that have been under pressure historically, says the analyst. He keeps an Overweight rating on the shares with a $425 price target.

ShowHide Related Items >><<
ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

06/08/21 Piper Sandler
Tweet suggests Abiomed study trending in right direction, says Piper Sandler
05/06/21 Raymond James
Abiomed could face new competition from Boston Scientific, says Raymond James
04/29/21 Piper Sandler
Abiomed earnings selloff a buying opportunity, says Piper Sandler
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

ABMD Abiomed
$312.81 /

+10.1 (+3.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.